Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07185802

Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.

This clinical trial will evaluate the effectiveness of platelet-rich plasma (PRP) injections for patients with anterior cruciate ligament (ACL) injury. ACL injuries commonly cause knee instability, pain, and reduced function, and rehabilitation alone may not fully restore recovery in all patients. PRP is prepared from a small sample of the patient's own blood and contains natural growth factors that may promote healing and improve joint function.

In this study, participants will be randomly assigned to one of two groups. The experimental group will receive a single ultrasound-guided injection of PRP into the knee joint along with a standard rehabilitation program. The control group will receive the rehabilitation program alone.

Participants will be followed up at 3 weeks, 8 weeks, and 16 weeks after treatment. At each follow-up visit, knee function, pain level, and physical performance will be assessed using validated outcome measures. The primary aim is to determine whether PRP provides additional benefit compared with rehabilitation alone in improving function and reducing symptoms in ACL-injured patients.

This study will provide new evidence about the role of PRP in ACL management, which may help guide future treatment decisions.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Anterior Cruciate Ligament

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bangabandhu Sheikh Mujib Medical University

Dhaka, 1000, Bangladesh

Location status: Recruiting

Location contact

Dr. Isfath Fauzia, MBBS

CONTACT

[email protected]

+8801744801604

Dr. Isfath Fauzia, MBBS

PRINCIPAL_INVESTIGATOR

Dr. Nazmul Hassan, MBBS

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes who are older than 18 years and younger than 50 years
  • 3 or Less than 3-months history of knee injuries
  • ACL injury MRI Grade 1 (Low) and medium Grade 2 (Medium) grade
  • ACL injury associated with Grade 1 or 2 Posterior cruciate ligament (PCL) tear and/or Grade 1 or 2 meniscal tear
  • The Complete Blood Count (CBC) report shows a hemoglobin > 10gm/dl and platelet count >150,000/microliter prior to the procedure
  • Capable of comprehending informed consent

Exclusion criteria

  • Patients who have had intra articular corticosteroid injections in the index knee during the last 12 weeks
  • Patients who are taking systemic steroid
  • Patients who are younger than 18 and older than 50 years
  • Those with a history of platelet disorders or on the therapeutic anticoagulant or anti platelet drugs
  • Hemoglobin below 10 gm/dl
  • Platelet count <150000/microliter
  • Complete tear of both bundles on MRI
  • Grade 3 or more PCL and meniscal tear on MRI
  • Previous or concurrent ligament reconstruction in the index knee joint.
  • Connective tissue disorders like Marfan Syndrome, Ehler-Danlos Syndrome etc.
  • Any inflammatory disease like Rheumatoid Arthritis, spondyloarthritis, gout, pseudogout etc involving the knee joint.

Treatment and study plan

PRP injection

Biological

Ultrasound guided intraarticular PRP is given to the patient with partial ACL tear

Other names: PRP group

conventional conservative method (physical therapy, functional bracing, lifestyle modification)

Other

conventional conservative method (physical therapy, functional bracing, lifestyle modification)

Other names: Rehabilitation

Primary outcomes

  1. Visual Analog Scale (VAS ): Change in pain intensity measured by Visual Analog Scale

    Time frame: Baseline, 3 weeks, 8 weeks, and 16 weeks after intervention.

    Pain intensity will be assessed using the Visual Analog Scale (0 = no pain, 10 = worst possible pain).

Secondary outcomes

  1. KOOS: Change in functional outcome measured by Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: Baseline, 3 weeks, 8 weeks, and 16 weeks after intervention.

    KOOS assesses five domains: pain, symptoms, activities of daily living, sport/recreation function, and knee-related quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Isfath Fauzia, MBBS

CONTACT

[email protected]

+8801744801604

Prof. Dr. Md. Ali Emran, MBBS, FCPS

CONTACT

[email protected]

+8801716161616

Sponsors and collaborators

Lead sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Other

Registry information

Acronym: ACL

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 22, 2025
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.